|
|
|
|
|
Legal status
Patent in force
| (51) | INT.CL. | A61P 31/14 | (2006.01) |
| A61K 38/06 | (2006.01) | ||
| A61K 38/07 | (2006.01) | ||
| A61K 38/08 | (2006.01) | ||
| C07K 5/08 | (2006.01) | ||
| C07K 5/10 | (2006.01) | ||
| C07K 5/12 | (2006.01) |
| (11) | Number of the document | 2540350 |
| (13) | Kind of document | T |
| (96) | European patent application number | 12181546.8 |
| Date of filing the European patent application | 2009-07-17 | |
| (97) | Date of publication of the European application | 2013-01-02 |
| (45) | Date of publication and mention of the grant of the patent | 2014-05-21 |
| (46) | Date of publication of the claims translation | 2014-08-25 |
| (30) | Number | Date | Country code |
| 135559 P | 2008-07-22 | US |
| (72) |
Harper, Steven, IT
Summa, Vincenzo, IT
Liverton, Nigel J., US
McCauley, John A., US
|
| (73) |
Merck Sharp & Dohme LLC,
126 East Lincoln Avenue, Rahway, NJ 07065,
US
MSD Italia S.r.l., Via Vitorchiano, 151, 00189 Rome, IT |
| (74) |
Jurga PETNIŪNAITĖ,
AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius,
LT
|
| (54) | Makrociklinio chinoksalino junginio, kuris yra HCV NS3 proteazės inhibitorius, deriniai su kitais HCV agentais |
| COMBINATIONS OF A MACROCYCLIC QUINOXALINE COMPOUND WHICH IS AN HCV NS3 PROTEASE INHIBITOR WITH OTHER HCV AGENTS |
| Payment date | Validity (years) | Amount | |
| 2025-06-16 | 17 | 347.00 EUR |
| 2026-07-17 |